ELOQUENT-3 study: elotuzumab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma - final analysis of overall survival (OS)

被引：0
|
作者：
Raab, M. S. [1 ]
Dimopoulos, M. [2 ]
Dytfeld, D. [3 ]
Grosicki, S. [4 ]
Moreau, P. [5 ]
Takezako, N. [6 ]
Hori, M. [7 ]
Leleu, X. [8 ]
LeBlanc, R. [9 ]
Suzuki, K. [10 ]
Richardson, P. G. [11 ]
Popa McKiver, M. [12 ]
Jou, Y. -M. [12 ]
Yao, D. [12 ]
Das, P. [12 ]
San-Miguel, J. [13 ]
机构：
[1] Heidelberg Univ Hosp, Dept Med 5, Heidelberg, Germany
[2] Natl & Kapodistrian Univ Athens, Sch Med, Athens, Greece
[3] Poznan Univ Med Sci, Dept Hematol & Bone Marrow Transplantat, Poznan, Poland
[4] Silesian Med Univ, Katowice, Poland
[5] Univ Hosp, Nantes, France
[6] Natl Hosp Org Disaster Med Ctr, Dept Hematol, Tokyo, Japan
[7] Ibaraki Cent Hosp, Dept Hematol, Ibaraki, Japan
[8] Ctr Hosp Univ Poitiers Miletrie, Poitiers, France
[9] Univ Montreal, Hop Maisonneuve Rosemont, Montreal, PQ, Canada
[10] Japanese Red Cross Med Ctr, Dept Hematol, Tokyo, Japan
[11] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA USA
[12] Bristol Myers Squibb, Princeton, NJ USA
[13] Clin Univ Navarra CUUN, Ctr Invest Med Aplicada, Inst Invest Sanitaria Navarra IDISNA, Ctr Invest Biomed Red Canc CIBERONC, Pamplona, Spain
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 2期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P310
引用
收藏
页码：87 / 87
页数：1
相关论文
共 50 条
  • [31] Prolonged overall survival with lenalidomide plus dexamethasone compared with dexamethasone alone in patients with relapsed or refractory multiple myeloma
    Weber, Donna
    Knight, Robert
    Chen, Christine
    Spencer, Andrew
    Yu, Zhinuan
    Zeldis, Jerome
    Olesnyckyj, Marta
    Dimopoulos, Meletios
    [J]. BLOOD, 2007, 110 (11) : 128A - 128A
  • [32] Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
    Shah, Jatin
    Usmani, Saad
    Stadtmauer, Edward A.
    Rifkin, Robert M.
    Berenson, James R.
    Berdeja, Jesus G.
    Lyons, Roger M.
    Klippel, Zandra
    Chang, Yu-Lin
    Niesvizky, Ruben
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (09): : 570 - +
  • [33] Elotuzumab in combination with pomalidomide and dexamethasone (EloPd) in relapsed refractory multiple myeloma (RRMM): a network meta-analysis
    Farrell, James
    Bertin, Nicolas
    Fischer, Claire
    Gauthier, Aline
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S169 - S170
  • [34] Pomalidomide, daratumumab, and dexamethasone after lenalidomide treatment in patients with relapsed or refractory multiple myeloma (RRMM): final overall survival analysis of the phase 2 MM-014 study
    Bahlis, Nizar
    Samaras, Christy
    Reece, Donna
    Sebag, Michael
    Matous, Jeffrey
    Berdeja, Jesus
    Shustik, Jesse
    Schiller, Gary
    Ganguly, Siddhartha
    Song, Kevin
    Seet, Christopher
    Acosta-Rivera, Mirelis
    Quick, Donald
    Anz, Bertrand
    Fonseca, Gustavo
    Liu, Hongjuan
    Gentili, Christian
    Siegel, David
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S162 - S162
  • [35] Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
    Richardson, Paul G.
    Facon, Thierry
    Bensinger, William I.
    Leleu, Xavier
    Campana, Frank
    Mace, Sandrine
    Chiron, Marielle
    van de Velde, Helgi
    Mikhael, Joseph
    [J]. BLOOD CANCER JOURNAL, 2021, 11 (03)
  • [36] Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
    Paul G. Richardson
    Thierry Facon
    William I. Bensinger
    Xavier Leleu
    Frank Campana
    Sandrine Macé
    Marielle Chiron
    Helgi van de Velde
    Joseph Mikhael
    [J]. Blood Cancer Journal, 11
  • [37] Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study
    Dimopoulos, Meletios A.
    Terpos, Evangelos
    Boccadoro, Mario
    Delimpasi, Sosana
    Beksac, Meral
    Katodritou, Eirini
    Moreau, Philippe
    Baldini, Luca
    Symeonidis, Argiris
    Bila, Jelena
    Oriol, Albert
    Mateos, Maria-Victoria
    Einsele, Hermann
    Orfanidis, Ioannis
    Kampfenkel, Tobias
    Liu, Weiping
    Kosh, Michele
    NamPhuong Tran
    Carson, Robin
    Sonneveld, Pieter
    [J]. BLOOD, 2022, 140 : 7272 - 7274
  • [38] Selinexor Plus Pomalidomide and Low Dose Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma
    Chen, Christine I.
    Sutherland, Heather J.
    Kotb, Rami
    Sebag, Michael
    White, Darrell J.
    Bensinger, William
    Gasparetto, Cristina J.
    Leblanc, Richard
    Venner, Christopher P.
    Lentzsch, Suzanne
    Schiller, Gary J.
    Lipe, Brea
    Del Col, Aldo
    Shah, Jatin J.
    Jeha, Jacqueline
    Saint-Martin, Jean-Richard
    Kauffman, Michael G.
    Shacham, Sharon
    Bahlis, Nizar
    [J]. BLOOD, 2018, 132
  • [39] Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design
    Richardson, Paul G.
    Attal, Michel
    Campana, Frank
    Le-Guennec, Solenn
    Hui, Ai-Min
    Risse, Marie-Laure
    Corzo, Kathryn
    Anderson, Kenneth C.
    [J]. FUTURE ONCOLOGY, 2018, 14 (11) : 1035 - 1047
  • [40] Selinexor, Pomalidomide, and Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma
    Chen, Christine I.
    Bahlis, Nizar
    Gasparetto, Cristina
    Tuchman, Sascha A.
    Lipe, Brea C.
    Baljevic, Muhamed
    Kotb, Rami
    Sutherland, Heather J.
    Bensinger, William I.
    Sebag, Michael
    Leblanc, Richard
    Venner, Christopher P.
    Schiller, Gary J.
    Lentzsch, Suzanne
    Callander, Natalie Scott
    Sheehan, Heidi
    Chai, Yi
    Kai, Kazuharu
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael G.
    White, Darrell J.
    [J]. BLOOD, 2019, 134
12345